Mineralys Therapeutics (MLYS) Equity Ratio (2022 - 2026)

Quarterly results put Equity Ratio at 0.98 for Q1 2026, up 1.58% from a year ago — trailing twelve months through Mar 2026 was 0.98 (up 1.58% YoY), and the annual figure for FY2025 was 0.98, up 5.2%.

Mineralys Therapeutics has reported Equity Ratio over the past 5 years, most recently at 0.98 for Q1 2026.

  • Equity Ratio reached 0.98 in Q1 2026 per MLYS's latest filing, roughly flat from 0.98 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.98 in Q2 2023 and bottomed at 0.46 in Q4 2022.
  • Median Equity Ratio over the past 5 years was 0.95 (2023), compared with a mean of 0.85.
  • The largest annual shift saw Equity Ratio soared 309.83% in 2023 before it decreased 7.15% in 2024.
  • Over 5 years, Equity Ratio stood at 0.46 in 2022, then soared by 309.83% to 0.96 in 2023, then decreased by 3.08% to 0.93 in 2024, then rose by 5.2% to 0.98 in 2025, then rose by 0.03% to 0.98 in 2026.
  • Business Quant data shows Equity Ratio for MLYS at 0.98 in Q1 2026, 0.98 in Q4 2025, and 0.96 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 0.04
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 0.42
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.73
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.77
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.21
10 Mineralys Therapeutics 2.50 Bn 2.50 Bn - 0.98

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.98
Dec 31, 2025 0.98
Sep 30, 2025 0.96
Jun 30, 2025 0.93
Mar 31, 2025 0.96
Dec 31, 2024 0.93
Sep 30, 2024 0.88
Jun 30, 2024 0.91
Mar 31, 2024 0.94
Dec 31, 2023 0.96
Sep 30, 2023 0.95
Jun 30, 2023 0.98
Mar 31, 2023 0.97
Dec 31, 2022 -0.46